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Abstract
Background: Survivors of transient ischemic attack (TIA) or stroke are at high risk for recurrent vascular events and 
aggressive treatment of vascular risk factors can reduce this risk. However, vascular risk factors, especially hypertension 
and high cholesterol, are not managed optimally even in those patients seen in specialized clinics. This gap between 
the evidence for secondary prevention of stroke and the clinical reality leads to suboptimal patient outcomes. In this 
study, we will be testing a pharmacist case manager for delivery of stroke prevention services. We hypothesize this new 
structure will improve processes of care which in turn should lead to improved outcomes.
Methods: We will conduct a prospective, randomized, controlled open-label with blinded ascertainment of outcomes 
(PROBE) trial. Treatment allocation will be concealed from the study personnel, and all outcomes will be collected in an 
independent and blinded manner by observers who have not been involved in the patient's clinical care or trial 
participation and who are masked to baseline measurements. Patients will be randomized to control or a pharmacist 
case manager treating vascular risk factors to guideline-recommended target levels. Eligible patients will include all 
adult patients seen at stroke prevention clinics in Edmonton, Alberta after an ischemic stroke or TIA who have 
uncontrolled hypertension (defined as systolic blood pressure (BP) > 140 mm Hg) or dyslipidemia (fasting LDL-
cholesterol > 2.00 mmol/L) and who are not cognitively impaired or institutionalized. The primary outcome will be the 
proportion of subjects who attain 'optimal BP and lipid control'(defined as systolic BP < 140 mm Hg and fasting LDL 
cholesterol < 2.0 mmol/L) at six months compared to baseline; 12-month data will also be collected for analyses of 
sustainability of any effects. A variety of secondary outcomes related to vascular risk and health-related quality of life 
will also be collected.
Conclusions: Nearly one-quarter of those who survive a TIA or minor stroke suffer another vascular event within a year. 
If our intervention improves the provision of secondary prevention therapies in these patients, the clinical (and 
financial) implications will be enormous.
Background
Epidemiological studies have shown that a number of
common conditions increase the risk of stroke and other
vascular diseases, and there is compelling evidence from
large randomized trials that treatment of such conditions,
especially hypertension and high cholesterol, can lead to
a significant reduction in the incidence and recurrence of
cardiovascular events [1-6]. We know that vascular risk
factors, in particular hypertension and high cholesterol,
are not managed optimally in patients after stroke or
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Page 2 of 9transient ischemic attack (TIA), even in those patients
seen in specialized stroke prevention clinics (SPCs) [7,8].
The recent Canadian best practice recommendations for
stroke care [9] highlighted this care gap and emphasized
that 'new strategies to support clinical practice...are
urgently needed'. Implementation of such strategies is
important because the risk of recurrent vascular events is
high in patients who have suffered a stroke or TIA (e.g., in
a recent study of 2,285 TIA survivors in Alberta, the rate
of stroke, myocardial infarction (MI), or death at one year
was 22%) [10]. Stroke prevention strategies need to
extend beyond the use of anti-platelet agents, anticoagu-
lation, and carotid endarterectomy, and start addressing
the need for more aggressive management of the key
stroke risk factors of hypertension and hyperlipidemia, as
well as consideration of other modifiable factors such as
medication adherence, smoking cessation, diabetes, exer-
cise, and weight loss.
Current stroke prevention practices
A recent analysis of data on over 2,000 patients evaluated
in the SPC at the University of Alberta Hospital (Edmon-
ton, Canada) confirmed the suboptimal management of
vascular risk factors in patients with recent stroke or TIA
in our health region [7,8]. Treatable risk factors (hyper-
tension and dyslipidemia) for stroke were seen in over
80% of patients, and the vast majority of these patients
were not controlled to recommended targets at any point
during the first year after being seen in our SPC [8]. Fur-
thermore, there did not seem to be any substantial
improvement in risk factor management in our health
region over the four years encapsulated within the pilot
data collection [7,8], nor in the intervening three years
since their publication. An analysis of the electronic data-
base maintained by Alberta Health Services for SPC
patients up to July 2008 revealed that 77% of patients at
baseline (and 68% at follow-up) did not meet currently
recommended low-density lipoprotein (LDL) cholesterol
targets for stroke/TIA patients of ≤2.0 mmol/L (Dr.
Thomas Jeerakathil, Chair of the Evaluation and Quality
Improvement Pillar of the Alberta Provincial Stroke
Strategy, personal communication, August 18, 2008), sug-
gesting little change will occur outside of a targeted inter-
vention.
It should be acknowledged that our current stroke pre-
vention system (comparable to other SPCs in Canada) is
largely consultative in that the stroke specialists provide
written recommendations to each patient's family physi-
cian but infrequently initiate or up-titrate blood pressure
(BP) or lipid-lowering medications, and SPC nurses are
not involved in medication adherence strategies or tele-
phone follow-up of this population. As such, patients are
'falling through the cracks' in our current system of care.
Our experience is virtually identical to that reported from
other SPCs [11]. Indeed, the under-treatment of vascular
risk factors is not restricted to stroke specialists and their
patients; it is also seen for other atherosclerotic condi-
tions [12-14]. The recently reported EXPRESS study
demonstrated (in a controlled before-after design) that
prompt initiation of various secondary prevention
manoeuvres in a British SPC (compared to their prior
practice of merely recommending therapy to primary
care physicians) resulted in substantial improvements in
risk factor management within the first month after TIA,
and an 80% reduction in recurrent stroke within three
months [15].
The crucial role of hypertension and lipid management for 
secondary prevention
Hypertension is the most important modifiable risk fac-
tor for vascular disease; approximately 22% of adult
Canadians have hypertension [16], and it is the most
common attributable cause for mortality in developed
nations [17]. Three-quarters (74%) of our SPC attendees
had a diagnosis of hypertension in our pilot study [7,8],
almost identical to the 71% prevalence of hypertension in
a large community-based cohort study of elderly US
stroke survivors [18]. There is a strong log-linear relation
between BP levels and vascular outcomes in both gen-
ders, across all age strata, and in all ethnic groups [3]; of
particular relevance to this proposal, lowering of systolic
BP by 5 mm Hg has been shown consistently to confer a
20% to 25% reduction in stroke rates (in both primary and
secondary prevention) which accrues relatively quickly
(within two years) [3,19,20]. Importantly, the benefits of
antihypertensive therapy in stroke/TIA survivors
enrolled in the PROGRESS trial were seen across all
quartiles of baseline BPs (including the lowest quartile in
which median baseline systolic pressures were 114 mm
Hg), with no evidence of a J-curve relationship [21]. In
addition, a recent analysis of 26 trials of angiotensin con-
verting enzyme (ACE) inhibitors demonstrated blood-
pressure independent reductions in cardiovascular
events, even in patients with baseline systolic BPs of less
than 140 mm Hg [22]. The current Canadian best prac-
tice recommendations for stroke care [9] advocate the use
of ACE inhibitors as first-line therapy and recommend
target systolic BPs of < 140 mm Hg in patients after the
acute phase of stroke or TIA, or < 130 mm Hg in those
with concomitant diabetes or chronic kidney disease. On
the basis of the meta-analysis [22] of 26 ACE inhibitor tri-
als and the secondary analyses from PROGRESS [21],
PRoFESS [23], and TRANSCEND [24] demonstrating
similar benefits accrued from renin-angiotensin system
inhibition, regardless of baseline BP, it seems reasonable
to initiate renin-angiotensin system inhibition if the sys-
tolic BP exceeds 130 mm Hg, a treatment strategy also
used in the EXPRESS Study [15] and consistent with both
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Small Subcortical Strokes Trial; clinicaltrials.gov identi-
fier: NCT00059306).
Similar data is becoming available confirming the effi-
cacy of statins in the primary and secondary prevention
of ischemic stroke [4,5,25]. Importantly, analogous to the
previous discussion regarding ACE-inhibition for hyper-
tension treatment, statins appear to be beneficial regard-
less of baseline LDL cholesterol, and the magnitude of
benefit is directly related to the degree of LDL cholesterol
reduction achieved [4,5,26]. Furthermore, in a recent
meta-analysis of all high-dose versus low-dose statin tri-
als (seven trials, 29,395 patients), we demonstrated an
additional 18% relative reduction in stroke (95% CI 5% to
29%) with high-dose statins [27].The current Canadian
best practice recommendations for stroke care [9] advo-
cate the use of statins in all patients after a stroke or TIA,
with a target goal of < 2.0 mmol/L LDL cholesterol.
Potential methods for improving secondary prevention 
after stroke/TIA
It has consistently been shown that multiple barriers
(patient-, physician-, and healthcare system-related) are
responsible for the lack of implementation of proven effi-
cacious therapies and traditional means of educating
practitioners (e.g., journal articles, continuing medical
education conferences, grand rounds lectures) are usually
ineffective in altering practice. We have previously out-
lined the rationale for our research program and high-
lighted various potential knowledge translation strategies
that may enhance the provision of evidence-based care
but which require evaluation [28]. Over the past five
years, our group has tested a number of these strategies
in randomized trials, including patient decision aids for
atrial fibrillation [29], multidisciplinary teams for patients
with diabetes [30] and osteoporosis [31], pharmacy
screening programs and reminder programs for patients
with angina and their primary care physicians [32], and
local opinion leader-based interventions for patients with
heart failure [33], hypertension [34], and coronary artery
disease [35]. In consultation with the stroke neurologists
and opinion leaders in stroke management in Alberta
(through the health promotion and prevention pillar of
the Alberta provincial stroke strategy), and taking into
account the results of our prior knowledge translation
studies, we developed a pharmacist case manager inter-
vention for secondary prevention after stroke/TIA that
we will evaluate in this trial
Why test a pharmacist case manager for secondary 
prevention after stroke?
Disease management programs that utilize a systematic
and multidisciplinary approach (usually nurse- or phar-
macist-based) for secondary prevention in patients with
ischemic heart disease have demonstrated substantial
improvements in atherosclerotic risk factors and signifi-
cant reductions in the incidence of recurrent disease in
many, but importantly, not all studies [36,37]. While 11
randomized trials have demonstrated that nurse or phar-
macist case managers who made medication adjustments
achieved better glycemic control in patients with type 2
diabetes than usual care by physicians or passive case
managers, who could only highlight the need for medica-
tion titration to each patient's primary care physician
[38], whether these benefits extend to other conditions
remains uncertain and is the premise of this trial.
Although several quasi-experimental studies or random-
ized trials with surrogate process outcomes (such as hav-
ing LDL measured) suggest that pharmacist case
management would be beneficial [39-46], the evidence on
clinical outcomes (such as changes in BP or LDL choles-
terol levels or rates of recurrent MI, stroke, or death) is
sparse and inconsistent between studies. Indeed, a
recently published systematic review of this literature
found that only 57% of studies suggested benefit with this
intervention, and the quality of the studies was such that
the authors concluded 'more high-quality studies are
needed' [46]. Perusal of the third issue of the 2009
Cochrane Library reveals two current Cochrane reviews
on this topic. One concluded that 'health professional
(nurse or pharmacist) led care appears to be a promising
way of delivering care but requires further evalua-
tion'[47], while the other concluded that 'the question of
whether pharmacists can manage drug therapy as well as
physicians remains unanswered due to a shortage of stud-
ies...more rigorous research is needed'[48]. Perusal of the
'Closing the Quality Gap' series on the Agency for
Healthcare Research and Quality (AHRQ) website con-
firmed that the intervention we have proposed to test is
promising but unproven [49]. Thus, although the use of a
pharmacist case manager to target secondary prevention
in patients with TIA or stroke holds great promise, as of
yet this is a promise unfulfilled, and a hypothesis which
needs to be tested.
Methods
Study design
This study will compare the intervention (pharmacist
case managers treating cardiovascular risk factors to tar-
get levels employing standardized protocols) to control
group (which, as detailed below, actually represents an
enhancement over usual care) utilizing a prospective,
randomized, controlled open-label with blinded ascer-
tainment of outcomes (PROBE) design. The individual
patient will be the unit of allocation, the unit of analysis,
and the unit of causal inference.
Study setting
All three SPCs in Edmonton, Canada (population 1.1 mil-
lion people) are participating in this trial.
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Patients older than 18 years of age, with a stroke or TIA,
who are evaluated at a SPC are eligible for the study if
they are confirmed by a stroke specialist to have had an
ischemic stroke or TIA within the past year and have sys-
temic hypertension (average systolic BP over two visits
exceeding 140 mmHg), fasting LDL cholesterol exceeding
2.0 mmol/L, or total:high-density lipoprotein (HDL) cho-
lesterol ratio exceeding 4.0.
Patients will be excluded if any one of the following cri-
teria apply:
1. Neurological event considered to be due to hemor-
rhage (e.g., intracranial hemorrhage, subarachnoid hem-
orrhage), cardiac embolus related to structural heart
disease (valve abnormality, atrial or ventricular septal
defect, endocarditis), or trauma (as defined by stroke spe-
cialists).
2. Participation in a concurrent trial related to stroke or
vascular disease.
3. Any condition that would preclude treatment benefit
or 12-month follow-up, including foreshortened life-
expectancy (e.g., active malignancy), hypertensive
urgency (clinic systolic BP ≥200 mm Hg), or severe
comorbidities.
4. Institutionalized in a long-term care facility.
5. Impaired cognition (scored ≥5 on the Short Portable
Mental Status questionnaire) [50].
6. Refractory hypertension or hyperlipidemia (levels
uncontrolled despite already being on three antihyper-
tensive drugs at maximal dose if hypertension is their
inclusion criterion, or on maximal dose statin if hyperlip-
idemia is their inclusion criterion).
Experimental arms
Control
Calling our control arm 'usual care' would be a misnomer,
because it refers to usual care provided via specialized
SPC and monthly visits with a study nurse. All three SPCs
that will enroll patients have standardized approaches,
protocols, and guidelines with respect to definitions and
diagnoses of stroke and TIA; routine investigations to
determine potential benefit of surgical approaches; rou-
tine application of anti-platelet medications; and routine
suggestions to primary care physicians with respect to
vascular risk factors such as hypertension, dyslipidemia,
smoking, and other lifestyle issues. However, similar to
other jurisdictions, our SPC current practice, confirmed
in our pilot data [7,8] suggests that these clinics do not
undertake active ongoing management of vascular risk
factors but rather instead provide suggestions and direc-
tions to each patient's primary care physician. Patients
randomized to the control arm will receive the same edu-
cational materials about stroke risk factors and medica-
tion adherence as the intervention patients, will be seen
monthly by a study nurse, will have the same number of
BP measurements, and will have a fax sent to their family
physician after each study visit reporting their BP and
current medications. Of note, our control arm actually
represents the intervention used in our recently pub-
lished SCRIP-HTN trial in individuals with diabetes
which resulted in a 5 mm Hg reduction in systolic BPs
compared to usual care (p = 0.03) [34]. Thus, some might
consider our study to be an active-comparator trial.
Intervention
Over and above usual care, our intervention will include
intensive pharmacist case-management, consisting of
monthly follow-up visits with the study pharmacist for
six months that will be independent of any planned fol-
low-up with the SPC or family physicians. At each visit,
the study pharmacist will monitor the patient's BP and
lipid levels and will initiate and/or titrate antihyperten-
sive and/or hypolipidemic therapy as appropriate. The
study pharmacist will follow treatment algorithms consis-
tent with current Canadian national guidelines [51,52].
The pharmacist will emphasize medication and lifestyle
adherence with patients and their caregivers, using the
cardiovascular risk profile as an educational aid as per
prior studies by our group [53,54]. The pharmacist will
also send a fax to the primary care physician after each
study visit outlining the status of that patient's atheroscle-
rosis risk factors and any therapy adjustments made at
that visit.
Study procedures (Figure 1)
Screening
After initial assessment in participating SPCs (which will
include standard SPC workup, including collection of
data elements for the ABCD2 score [55], carotid dopplers,
CT scan, fasting lipid profile, fasting glucose, electrolytes,
creatinine, complete blood count (CBC), liver function
tests, glycosylated hemoglobin, and electrocardiogram),
all potentially eligible patients who consent to further
screening for the trial will be assessed in person at a study
screening visit within two weeks by a research assistant.
At this visit, they will have their BP measured using the
BpTRU® device (VSM MedTech, Vancouver, BC, Canada).
If their average systolic pressure (averaged between the
SPC measurement and the average measurement at the
study screening visit) exceeds 140 mm Hg or their fasting
lipid profile reveals LDL cholesterol exceeding 2.0 mmol/
L or total:HDL cholesterol ratio > 4, and they provide
written consent for the study, baseline case report forms
will be completed.
Randomization
Patients will be randomized 1:1 to control or interven-
tion. Randomization will be done centrally by computer-
generated random numbers, and a secure internet-based
allocation method that ensures allocation concealment
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fied by participating SPC. As this study is unblinded, vari-
able sized blocked randomization will also be used to
preserve allocation concealment. Because our interven-
tion is distinct from usual care and current standards of
care in participating clinics are well demarcated, the risk
of contamination (by altering the practices of physicians
in participating SPCs) is low. Furthermore, our pilot data
suggests that the ratio of patients enrolled to primary care
physicians affected in this study is essentially 1:1--that is,
it is unlikely that any one of the almost 950 primary care
physicians in Edmonton will have more than one patient
enrolled in this study. Thus, the patient will be the unit of
randomization and analysis in this study.
BP measurement
Systolic BP will be ascertained at all study visits using the
BPTru® device, with six readings performed one minute
apart in the arm with the highest reading, and last five
readings averaged. These are similar to the methods used
in the Canadian health measures survey [56] and the
third national health and nutrition examination survey
(NHANES III). The BpTRU® automated device has been
approved by both the Canadian Hypertension Education
Program and the Association for the Advancement of
Medical Instrumentation.
Outcomes
Because this is an active control trial, we expect improve-
ments in all aspects of care in the control arm--due to
both active intervention by stroke specialists within the
SPCs and the referring primary care physicians in
response to the monthly reminders about each study par-
ticipant's BP, various secular/temporal influences as they
relate to vascular risk reduction, study volunteer and
Hawthorne effects, and regression to the mean. The
importance of a control group cannot be over-empha-
sized. For example, in the ESP-CAD trial, we found a 50%
absolute improvement in statin management in the con-
trol group [35]. Therefore, all continuous measurements
will be 'changes' from baseline to six months, comparing
the changes achieved in the intervention group with
those in the control group.
Primary outcome
Because hypertension and dyslipidemia are the most
important risk factors for recurrent cardiovascular events
in patients with ischemic stroke or TIA [5,57,58], a com-
posite outcome incorporating both has been selected as
the primary study outcome. Specifically, the primary out-
come is the proportion of subjects who attain 'optimal BP
and lipid control'(defined as systolic BP ≤140 mm Hg and
fasting LDL cholesterol ≤2.0 mmol/L) at six months
according to allocation status.
Secondary outcomes
Secondary outcomes will include change in systolic BP at
six months versus baseline, proportion achieving BP tar-
get (SBP ≤140 mmHg), change in LDL cholesterol at six
months versus baseline, proportion attaining LDL choles-
terol targets (LDL ≤2.0 mmol/L), proportion attaining
total:HDL cholesterol ratios ≤4.0, changes in the cardio-
vascular disease life expectancy model score [53],
changes in other vascular risk factors (waist circumfer-
ence, body-mass index, self-reported smoking rates, and
physical activity), and therapy changes (including num-
ber, dosing, and self-reported adherence with antihyper-
tensive and lipid lowering agents). Although differences
Figure 1 Prevention Trial Study Procedures. TIA = transient isch-
emic attack, SPC = stroke prevention clinic, SBP = systolic blood pres-
sure, GP = general practitioner.
Neurology Screening
Patients with ischemic stroke/TIA seen at Stroke Prevention Clinic (SPC)
If SBP > 140 mmHg or LDL cholesterol >2mmol/L or total:HDL cholesterol 
>4 , Study Information Sheet given to patient
Verbal consent for study team to contact patient
Intervention
Monthly study visits (x6) 
with pharmacist who 
applies the hypertension  
and lipid treatment 
algorithms
Education about stroke 
prevention strategies, 
medication adherence
Faxes GP with BP 
measurements, 
medication changes  
after each visit
Primary Outcome:  6 month 
Study Visit
No further contact until




Study personnel screen SPC chart
Administer further screening tools, including 
cognitive assessment via telephone
Baseline Visit
BP measured
If average SBP from SPC visit and this visit is  > 140 mmHg 
or LDL cholesterol >2mmol/L or total:HDL cholesterol >4 , 
written consent and randomization
Baseline data collection
Study information faxed to general practitioner (GP)
within 2 weeks of SPC Visit
within 2 weeks of Study 
Screening Visit
Control
Monthly study visits (x6) 
with Study nurse
Education about stroke 
prevention strategies and 
importance of medication 
adherence
Faxes BP measurements to 
patient’s GP after each 
visit
Primary Outcome:  6 month 
Study Visit
No further contact until
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tion of this trial, data will be collected on all-cause hospi-
talizations, emergency room visits, primary care
physician visits, mortality, and clinical events (confirmed
by an independent outcome validation committee,
blinded to allocation status) such as stroke, TIA, MI, or
revascularization. We will also examine humanistic out-
comes such as changes in EUROQOL(EQ)-5D [59] and
the modified Rankin scale [60] in intervention versus
control patients over the course of the trial and will col-
lect direct and indirect costs to conduct a formal cost-
effectiveness analysis if the intervention is efficacious.
Finally, in order to explore the sustainability of any
changes induced by the six-month intervention, we will
examine changes in the primary and secondary outcomes
at twelve months in both study arms (i.e., six months after
the intervention stopped). Note that all data will be col-
lected during active follow-up in the twelve-month study
period, and further clinical event data will be collected by
passive follow-up (for up to five years) through annual
linkage to provincial physician billing databases/Cana-
dian Institute for Health Information (CIHI)/provincial
vital statistics and registered persons databases after
completion of this study as per prior studies by our group
[61].
Outcomes ascertainment
The primary and secondary outcomes will be collected
and analyzed in an independent and blinded manner by
research personnel who have not been involved in the
patient's care and will be blinded to patient's randomiza-
tion group and baseline measurements (including BPs).
Thus, although patients and their physicians cannot be
masked to the fact that they are in the intervention arm,
those collecting outcome data and analyzing the data will
be blinded.
Systolic BP will be ascertained at baseline and at six
months using the BPTru® device. All study-related lab
measurements, collected at baseline, six, and 12 months,
will be drawn and independently analyzed at one central
lab (Dynalife Dx, Edmonton, Alberta, Canada). All survey
instruments will be administered locally at baseline, 6,
and 12 months, but collated and analyzed at one central
lab, the Epidemiology Coordinating and Research (EPI-
CORE) Centre, Division of Cardiology, University of
Alberta. Clinical events reported by patients, their family
members, or their primary care physicians will be inde-
pendently validated by the central outcome validation
committee that will be blinded to patients' allocated
treatment arms. All patients will be asked to sign the
appropriate consent and privacy forms needed to permit
examination of clinical outcomes, resource use, and vital
status at six months and one year (to cross-check and val-
idate data collected at the active follow-up appoint-
ments), and at five and ten years, to gain further insights
into long-term clinical event rates.
Sample size
In a survey of members of the divisions of neurology and
general internal medicine at the University of Alberta, we
determined that the 'minimal' clinically important differ-
ence for this particular intervention to be considered use-
ful was a 10% absolute improvement in the proportion of
patients achieving 'optimal BP and lipid control' over and
above usual care. After six months, we estimate that no
more than 5% of control patients will have attained our
composite primary outcome (given that patients who are
at goal BP and lipid levels at baseline will be excluded
from this study). We calculated our sample size to detect
a 10% absolute increase in the primary outcome, set the
alpha error rate at 0.05 (2-sided), and the beta error at
0.20 (power 80%); this yielded a minimal necessary sam-
ple size of 140 patients per study arm.
The calculated sample size will also provide 80% power
(assuming a standard deviation of 15 mm Hg, as recently
found in our trial of diabetic hypertensive patients) [34]
to detect a 5 mm Hg between-group difference in systolic
BP at six months with alpha of 5% for a two-sided test.
Based on a review of the literature, consensus of the
investigators, and consensus of over two dozen members
of the Evidence-Based Recommendations Task Force of
the Canadian Hypertension Education Program (sur-
veyed by Dr. McAlister, in his role as Chair of the Central
Review Committee for the Evidence-Based Recommen-
dations Task Force of the Canadian Hypertension Educa-
tion Program]), a 5 mmHg sustained difference in SBP,
over and above usual care, would be considered clinically
meaningful.
A sample size of 140 patients per group will also pro-
vide 85% power (assuming a standard deviation of 0.84
mmol/L, as recently found in our trial in patients with
coronary disease) [35] to detect a 0.3 mmol/L between-
group difference in fasting LDL cholesterol at six months
with alpha of 5% for a two-sided test. This sample size
will also provide 85% power (assuming a standard devia-
tion of 14%, as recently found in a trial of 2,687 patients)
[53] to detect a 5% between-group difference in projected
five-year risk of cardiovascular disease at six months with
alpha of 5% for a two-sided test.
One interim analysis is planned, when 140 patients
(50% of the projected minimum sample) have had their
six-month outcomes ascertained. An independent data
and safety monitoring board will examine whether our
assumptions about changes in BP and lipid levels (as well
as standard deviations) are consistent with the data at
that time and will make a recommendation to the study
steering committee about whether or not we should con-
tinue the study as planned, increase enrollment, or stop
the study due to futility. Although we had initially pro-
posed a total sample size of 340 (reflecting a 20% inflation
above the minimum necessary sample size to account for
potential losses to follow-up), in our most recent trial of
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low-up were only 3% due to the new province-wide elec-
tronic health record in Alberta. Thus, we will examine
losses to follow-up in the first 140 patients randomized to
determine how much 'inflation factor' we must apply to
the sample size to ensure we have outcomes for at least
140 patients per arm at 6 months.
Statistical analysis
All sociodemographic and clinical characteristics at base-
line and follow-up will be summarized using percentages
for categorical variables and medians (interquartile
range) for continuous variables. Chi square tests will be
used to compare the proportion of patients who attain
'optimal BP and lipid control' at six months (because the
proportion at baseline will be zero by definition), as well
as other binary secondary outcomes such as proportions
that achieve target BP and lipid levels. Patient and health
system factors associated with meeting BP and lipid goals
will be assessed in multivariate analyses. To compare
changes in systolic BP, LDL cholesterol, and total:HDL
cholesterol ratios between intervention and control, we
will use 2-sample independent t-tests. In the event that
any baseline characteristics are not balanced between
study groups, we will employ multivariate extensions of
our primary analytic plan (i.e., substituting multiple lin-
ear regression for t-test or multiple logistic regression for
Chi square test), adjusting for any clinically important
(i.e., greater than 10% imbalance between arms) or statis-
tically significant (i.e., p-value of < 0.10 between arms)
differences observed between groups.
All analyses will be by intention to treat. Missing data at
the six-month follow-up assessment will be imputed with
a 'baseline-observation carried forward' strategy; this
approach conservatively assumes that all subjects lost to
follow-up have had no change in their BP or lipid levels.
As a sensitivity analysis for this assumption, we will also
analyze the data in an 'on-treatment' analysis, using only
those cases with complete follow-up data for each analy-
sis.
Data management
All data will be collected using standardized data sheets
and data collation, entry, quality assurance, and analysis
will be carried out by the EPICORE Centre.
Ethical considerations
Each patient will be given written information about the
study and written informed consent will be obtained
prior to study entry. The study protocol was approved by
the Health Research Ethics Board, University of Alberta
(study ID Pro00001556). The funding for the study is
from two peer-reviewed grants. The funding sources (the
Alberta Heritage Foundation for Medical Research and
the Heart and Stroke Foundation of Canada) had no role
in the design of the study and will have no role in the con-
duct, analysis, interpretation, or reporting of the study,
nor access to the data.
Discussion
We report the protocol for a randomized, controlled trial
that aims to determine the effect of a pharmacist case
manager to improve control of BP and serum lipids in
patients with recent ischemic stroke/TIA. There is a large
and universally reported care gap in the prevention of
vascular disease--even in SPC attendees--and limited
data on interventions proven to improve outcomes in
patients with stroke or TIA. Studies in other chronic dis-
orders (e.g., coronary disease, heart failure, and diabetes
mellitus) offer hope that multifaceted interventions
employing pharmacist case managers may improve pre-
scribing/dosing of medications and adherence to medica-
tions, resulting in improved risk factor profiles and
clinical outcomes. However, it is important to develop
and prospectively investigate the role of a pharmacist
case management program in concert with current stan-
dard of care (i.e., SPCs) for survivors of stroke/TIA.
Because disease management programs do not always
work [36,62,63], and the benefits (if present) are often
condition-specific, such programs must be tested in con-
trolled trials, rather than just assuming they are benefi-
cial. Although ultimately the multifaceted program we
are proposing will be judged by its impact on clinical
events, this study has been designed to test the impact of
our program on important processes of care (medication
management and adherence) as well as intermediate out-
comes (such as BP and cholesterol levels) that are well-
validated as predictors of subsequent stroke and cardio-
vascular events.
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